Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: A randomised crossover trial

Diabetologia

Volumn 53, Issue 8, 2010, Pages 1576-1580

  Persson, F ^a   Rossing, P ^a   Reinhard, H ^a   Juhl, T ^a   Stehouwer, C D A ^b   Schalkwijk, C ^b   Danser, A H J ^c   Boomsma, F ^c   Frandsen, E ^d   Parving, H H ^e,f  

^a STENO DIABETES CENTER   (Denmark)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e Mental Health Services CPH   (Denmark)

^f AARHUS UNIVERSITY   (Denmark)

Author keywords

Albuminuria; Aliskiren; Diabetic nephropathy; Renin angiotensin system; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ALBUMIN; ALISKIREN; FUROSEMIDE; PLACEBO; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE; RENIN;

ALBUMINURIA; ARTICLE; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; ADULT; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS;

ADULT; ALBUMINURIA; AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FUMARATES; HUMANS; HYPERTENSION; RENIN;

EID: 77955518102     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-1789-6     Document Type: Article

References (10)

1. BM Brenner ME Cooper D de Zeeuw WF Keane WE Mitch H-H Parving 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861 869 10.1056/NEJMoa011161 1:CAS:528:DC%2BD3MXntlelsLk%3D 11565518
2. H-H Parving F Persson JB Lewis EJ Lewis NK Hollenberg 2008 Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 358 2433 2446 10.1056/NEJMoa0708379 1:CAS:528:DC%2BD1cXmvFKmtLY%3D 18525041 (Pubitemid 351793017)
3. KJ Schjoedt AS Astrup F Persson, et al. 2009 Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial Diabetologia 52 46 49 10.1007/s00125-008-1184-8 1:CAS:528:DC%2BD1cXhsVCmsrfJ 18974967
4. S Andersen P Rossing TR Juhl J Deinum H-H Parving 2002 Optimal dose of losartan for renoprotection in diabetic nephropathy Nephrol Dial Transplant 17 1413 1418 10.1093/ndt/17.8.1413 1:CAS:528:DC%2BD38XntVertrg%3D 12147788
5. F Persson P Rossing H Reinhard, et al. 2009 Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria Diab Care 32 1873 1879 10.2337/dc09-0168 1:CAS:528:DC%2BD1MXhtlehs7nL
6. J Bröchner-Mortensen 1972 A simple method for the determination of glomerular filtration rate Scand J Clin Lab Invest 30 271 274 10.3109/00365517209084290 4629674
7. F Persson P Rossing KJ Schjoedt, et al. 2008 Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes Kidney Int 73 1419 1425 10.1038/ki.2008.68 1:CAS:528: DC%2BD1cXmsFehsr4%3D 18337712 (Pubitemid 351770494)
8. GD Laverman SJ Bakker GJ Navis 2009 Optimal dosing of renin-angiotensin-aldosterone system blockers for renal protection: a solved issue? Diabetologia 52 1217 1218 10.1007/s00125-009-1328-5 1:STN:280: DC%2BD1MzhtF2ksQ%3D%3D 19294362
9. K Rossing KJ Schjoedt BR Jensen F Boomsma H-H Parving 2005 Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria Kidney Int 68 1190 1198 10.1111/j.1523-1755.2005. 00511.x 1:CAS:528:DC%2BD2MXhtVCjt73E 16105050 (Pubitemid 43246436)
10. S Feldt U Maschke R Dechend FC Luft DN Muller 2008 The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling J Am Soc Nephrol 19 743 748 10.1681/ASN.2007091030 1:CAS:528:DC%2BD1cXkvFOhsbo%3D 18235083